CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.
about
Beta-lactamase inhibitors from laboratory to clinicThree decades of beta-lactamase inhibitorsTargeting Antibiotic ResistanceChemistry and biosynthesis of clavulanic acid and other clavamsPharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.beta-lactams: variations on a chemical theme, with some surprising biological results.Pharmacokinetics of an ampicillin-sulbactam combination after intravenous and intramuscular administration to sheep.Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Bioactives of microbes isolated from Western Ghat belt of Kerala show β-lactamase inhibition along with wide spectrum antimicrobial activity.In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin.Chemistry of newer antibiotics directed toward overcoming bacterial resistanceIn vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitorPenetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitisTherapeutic trial and pharmacokinetics of sulbactam for uncomplicated gonorrhea in menEffects of ampicillin plus sulbactam on bowel flora in patients undergoing colorectal surgeryActivity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase productionPharmacokinetics of sultamicillin in mice, rats, and dogsImipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.In vitro effects of beta-lactams combined with beta-lactamase inhibitors against methicillin-resistant Staphylococcus aureusPharmacokinetics of ampicillin and sulbactam in patients undergoing heart surgeryCriteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid.The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins.In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combinationInterpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disksAntimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).Antimicrobial therapy for the elderly patient.β-Lactams and β-Lactamase Inhibitors: An Overview.Structure-function studies of Ser-289 in the class C beta-lactamase from Enterobacter cloacae P99.The potential use of mechanism-based enzyme inactivators in medicine.Structure-activity relationships amongst beta-lactamase inhibitors.Methodology for the study of beta-lactamases.New sensitive bioassay for sulbactam in bovine tissues.Correlation of the effect of beta-lactamase inhibitors on the beta-lactamase in growing cultures of gram-negative bacteria with their effect on the isolated beta-lactamase.Covalent binding of moxalactam to cephalosporinase of Citrobacter freundii.In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.
P2860
Q24617277-252803DA-1FFF-4A89-8A6E-A22164541F13Q24646623-3BDB11F5-E484-4116-891A-950787341951Q28078130-7EB41006-ACF9-4FF7-899C-AB0C4E88B4C1Q28247865-8E141DF5-B452-47F1-BAAC-764934318302Q33689403-23A57831-4081-4D3A-9C63-20CD9E2E4E0CQ33789695-3A180B06-7C12-43C1-864B-9C136843E74CQ33923512-B7B0246A-9175-40A8-B16D-146D9D86272AQ34042624-F8886F5F-5E82-4262-AADD-A4754AF32BC7Q34164869-66B7737E-521E-49C5-AF8B-2D68221B8CA0Q34519808-D9BD9DD1-5B35-4BAC-87AF-6722B64BB434Q35119472-CDA878FE-0C37-46D3-B8AC-BBF13BB4A3EDQ35282939-881B306D-FF88-4EDA-B6F7-F84B4CFB0F1BQ35299177-2BDF06D8-3F8D-45C1-BCEA-9B76B0890788Q35347789-EB7AC9D4-9841-47FF-8870-B4AD44B77D2BQ35350158-1C353E0C-1275-4F7B-8E82-A5C47A356E3FQ35543154-EA54EF34-ACEE-49A6-84AC-45F272301297Q35640481-ED40FF11-46BA-420D-B396-CD3F8733DB92Q35714317-5F2F2BE1-ADF0-4FF2-A7C3-E0D255EBF780Q35716328-E8B69F14-3855-4EF8-9A61-34BC52C9AA14Q35759894-4188D77D-3B53-4C4C-A54F-71F7B6115263Q35938407-9B3A3FB0-B3A0-4961-BA66-2CBE4B5349EEQ36198315-78C5AB80-2915-4CBA-AA2D-5DDDA1896A54Q36754797-AEC125F0-1602-4AE6-8D4C-596D47CA4211Q37141847-0CBAF53E-02F0-4825-9ADA-4AB97DA20A12Q37150848-7232EB96-4A50-4884-B30F-A7A937D93158Q37204410-D9FA6678-8C6A-4D5E-868D-C468A9339329Q37218996-FA0A7F9B-FA49-4BA0-8BAF-E99045953CDDQ37220644-A6805A58-C6D8-443F-95A1-6BC9EB753B1EQ37260244-29B0A6C8-76AC-47EF-B9A6-94A6D76CF4DAQ37335781-62B1B6B7-04EF-457F-8456-26BEB84B6A54Q38006505-CB775F39-3B91-49F2-92DA-2EDE1AFD16BDQ38872374-07EB8753-3B94-49A4-9997-073FDC855DE9Q39470234-99E5B558-8A23-4725-A414-E14286310519Q39568018-3C91572A-CEA2-4FE2-B6DE-7CBAA774C7D6Q39706458-824F4B1E-8872-4BE1-9F53-BC181CEC548EQ39742899-28FD5351-27BB-4944-814C-C38391B8C468Q39832272-778AF0B4-0F7E-48C4-B026-79E23F79FA5AQ39833500-98A7DC76-2667-442E-A3E4-65E2CAC0CA40Q39849854-34C29697-34F4-420C-85C9-AE422036DE89Q39849981-E1CB8A24-8C03-43B5-9147-89D1549A776B
P2860
CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
CP-45,899, a beta-lactamase in ...... teriological characterization.
@en
type
label
CP-45,899, a beta-lactamase in ...... teriological characterization.
@en
prefLabel
CP-45,899, a beta-lactamase in ...... teriological characterization.
@en
P2093
P2860
P356
P1476
CP-45,899, a beta-lactamase in ...... teriological characterization.
@en
P2093
P2860
P304
P356
10.1128/AAC.14.3.414
P407
P577
1978-09-01T00:00:00Z